Protara Therapeutics, Inc. (TARA)
NasdaqGM · USD · Healthcare · Biotechnology
$2.35 (+0.86%) as of
Key statistics
- Market cap
- 138.87M
- Forward P/E
- -1.39
- EPS (TTM)
- -1.3600
- Dividend yield
- 0.00%
- 52-week range
- 2.2800 – 7.8200
- Beta
- 1.47
- Profit margin
- 0.00%
- Analyst target
- $25.71
- Volume
- 892.64k
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, NY, United States
- Employees
- 46
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.